ArticleOncology letters2026
Preoperative CA125 and metabolic factors associated with high-risk pathology in endometrial cancer.
Article in Oncology letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Molecular classification is now central to endometrial cancer risk assessment, but its implementation in routine practice varies across clinical settings. Against this background, the present retrospective study examined whether routinely available preoperative CA125 and metabolic factors are associated with postoperative high-risk pathological features in endometrial cancer. A total of 188 patients with surgically treated, pathologically confirmed endometrial cancer at Cangzhou Central Hospital Affiliated to Hebei Medical University (Cangzhou, China) between January 2024 and January 2026 were included. Clinical characteristics, metabolic indicators, preoperative CA125, postoperative pathological variables and available molecular classification data were collected. The primary outcome was the presence of any high-risk pathological factor, defined as high-grade/aggressive histology, deep myometrial invasion, lymphovascular space invasion (LVSI), cervical stromal involvement or lymph node metastasis. Overall, 98 patients (52.1%) had at least one high-risk pathological factor. Molecular classification was missing or undetermined in 66 patients (35.1%); these results were therefore treated as contextual exploratory information. In the prespecified multivariable model, age [odds ratio (OR)=1.061; 95% CI, 1.019-1.108; P=0.005] and log(CA125) (OR=2.059; 95% CI, 1.375-3.242; P<0.001) were associated with the composite high-risk pathological phenotype. Exploratory analyses of individual endpoints showed the most consistent CA125 associations with LVSI positivity and lymph node metastasis. BMI, diabetes, hypertension, metabolic syndrome and routine lipid indicators did not show reproducible associations with high-risk pathological status. Overall, higher preoperative CA125 was independently associated with the composite adverse pathological phenotype and may provide complementary preoperative risk information pending prospective validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.